Adherencia al tratamiento antihipertensivo en pacientes de un hospital terciario en Lima, Perú

Angy Aguilar-Lizarme; José Amado-Tineo

doi:10.17843/rpmesp.2026.431.15462

Authors

Angy Aguilar-Lizarme Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú. https://orcid.org/0000-0001-7808-0248
José Amado-Tineo Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú. Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú https://orcid.org/0000-0002-3286-4650

DOI:

https://doi.org/10.17843/rpmesp.2026.431.15462

Keywords:

Treatment Compliance and Adherence, Hypertension, Antihypertensive

Abstract

In Peru, there are few reports on pharmacological adherence in patients with arterial hypertension. In this context, the present study aimed to determine adherence to antihypertensive treatment in patients treated at a tertiary-level social security hospital in Lima. A cross-sectional study was conducted in 250 hospitalized patients, over 18 years of age, with a diagnosis of primary arterial hypertension on pharmacological treatment. Adherence was evaluated using the Morisky questionnaire (MMAS-8), and variables such as prescribed medication, age, sex, marital status, and educational level were collected. 56.4% of the participants were male and 86.4% were over 60 years old. It was observed that 42% presented low pharmacological adherence and 58% medium adherence, with no cases of high adherence recorded. Monotherapy was the most frequent regimen (48%), with losartan, nifedipine, and enalapril being the most prescribed drugs. Finally, significant differences were identified between adherence to antihypertensive treatment and educational level and the number of drugs.

Downloads

Download data is not yet available.

References

Organización Mundial de la Salud. First WHO report details devastating impact of hypertension and ways to stop it. Ginebra: OMS; 2023.

Podzolkov V, Bragina A, Medvedev I, Vetluzhskaya MV, Abramova AA, Loria IZ, et al. Compliance to treatment and its role in solving the problem of uncontrolled hypertension. Cardiovascular Therapy and Prevention. 2023;22(3):45-52. doi: 10.15829/1728-8800-2023-3547.

Montealegre L, Amador E, Pulido T, Cabrera C, Rivera A, Rebolledo R. Main factors that determine adherence to pharmacological treatment in hypertensive patients: A systematic review. Journal of Hypertension. 2022;40(6):1123-1135. doi: 10.1097/01.hjh.0000838740.81890.19.

Lee E, Poon P, Yip B, Bo Y, Zhu MT, Yu CP, et al. Global burden, regional differences, trends, and health consequences of medication non-adherence in patients with hypertension during 2010-2020: A systematic review and meta-analysis. JAHA. 2022;40(5):887-901. doi: 10.1161/JAHA.122.026582.

Organización Mundial de la Salud. Directriz para el tratamiento farmacológico de la hipertensión en adultos. Ginebra: OMS; 2022. Disponible en: https://www.who.int/es/publications/b/59565.

Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124-1140. doi: 10.1161/CIRCRESAHA.118.313220.

Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, et al. Knowledge about disease, medication therapy, and related medication adherence levels among patients with hypertension. Medicina (Kaunas). 2019;55(11):715-723. doi: 10.3390/medicina55110715.

Algabbani F, Algabbani A. Treatment adherence among patients with hypertension: findings from a cross-sectional study. Clinical Hypertension. 2020;26(1):1-9. doi: 10.1186/s40885-020-00151-1.

Campos KJ, Almeida EW, Freitas JA, Vieira AK, Dias R, Rodrigues W, et al. Factors associated with adherence to pharmacological treatment by hypertensive patients. Concilium. 2023;23(5):45-56. doi: 10.53660/CLM-1446-23G16A.

Carrillo-Larco R, Guzman-Vilca W, Bernabe-Ortiz A. Risk-based antihypertensive treatment allocation in Peru: comparison of local and international guidelines. Lancet Regional Health - Americas. 2021;3:100022. doi: 10.1016/j.lana.2021.100022.

Ventocilla N, Condorhuamán Y. Adherencia farmacoterapéutica en pacientes hipertensos en el Centro Integral del Adulto Mayor de Santa Anita – Lima. Ciencia e Investigación. 2020;23(1):45-52. doi: 10.15381/ci.v23i1.18716.

Valencia-Monsalvez F, Mendoza-Parra S, Luengo-Machuca L. Evaluación de la escala Morisky de adherencia a la medicación. Rev Peru Med Exp Salud Publica. 2017;34(2):245-249. doi: 10.17843/rpmesp.2017.342.2206.

Pocohuanca-Ancco L, Villacorta J, Hurtado Y. Factores asociados a la no adherencia al tratamiento en pacientes hipertensos. Rev Cuerpo Med HNAAA. 2021;14(3):125-132. doi: 10.35434/rcmhnaaa.2021.143.1252.

Barón JO, Fernández-Ávila DG, Cárdenas S, Duitama EL, Calderón TV, Romero LA, et al. Adherencia al tratamiento de pacientes con hipertensión arterial en un hospital universitario de Colombia. Rev Colomb Nefrol. 2025; 12(1):e806. doi: 10.22265/acnef.12.1.806.

Quynh C, Samuelsen P, Leinky H, Wisløff T, Wilsgaard T, Eggen AE. Comparing sociodemographic characteristics of participants and non-participants in population-based studies. BMC Public Health. 2023;221:1-8. doi: 10.1186/s12889-023-15928-w.

Mendoza V. Nivel de adherencia Terapéutica y control de hipertensión arterial en pacientes del Centro de Salud El Álamo [Tesis de pregrado]. Lima: Universidad Nacional Federico Villarreal; 2021.

Zapatini D, Ortiz I. Adherencia terapéutica en pacientes hipertensos del consultorio de Clínica Médica del Hospital de Clínicas. An Fac Cienc Méd. (Asunción), 2021; 54(2): 89-96. doi: 10.18004/anales/2021.054.02.89.

Altamirano G, Bringas E, Ventura E. Adherencia al tratamiento terapéutico en pacientes con hipertensión arterial. Cuidado & Salud Pública. 2021;1(2):18-25. doi: 10.53684/csp.v1i2.18.

Sotomayor-Perales JL, Delgado-Flores CJ, Carrión-Arcela JP, Galván-Barrantes DA, Mejía-Azañero J, Núñez-Osorio L, et al. Guía de práctica clínica para el manejo de la Hipertensión arterial esencial en el Seguro Social del Perú (EsSalud). Rev Cuerpo Med HNAAA. 2024;17(1). doi: 10.35434/rcmhnaaa.2024.171.1969.

Gorostidi M, Gijón-Conde T, De la Sierra A, Rodilla E, Rubio E, Vinyoles E, et al. Guía práctica sobre el diagnóstico y tratamiento de la hipertensión arterial en España. Hipertensión y Riesgo Vascular. 2022;39(4):188-201. doi: 10.1016/j.hipert.2022.09.002.